Table 3. Baseline characteristics of the fourth dose cohort.
N (%) | |
---|---|
Baseline seronegative | 7 (39%) |
Baseline low positive (spike ab <1000 AU/mL) | 11 (61%) |
Cancer diagnosis | |
CLL | 7 (39%) |
Waldenstrom’s macroglobulinemia | 3 (17%) |
DLBCL | 2 (11%) |
Multiple myeloma | 2 (11%) |
Mantle cell Lymphoma | 1 (6%) |
Marginal zone lymphoma | 1 (6%) |
Hodgkins lymphoma | 1 (6%) |
MDS | 1 (6%) |
Fourth dose vaccine type | |
BNT162b2 | 15 (83%) |
Ad26.CoV2.S | 3 (17%) |